Drug Profile
Tenalisib - Rhizen Pharmaceuticals
Alternative Names: RP 6530Latest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator Rhizen Pharmaceuticals
- Class Amines; Antineoplastics; Chromans; Fluorobenzenes; Purines; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors; Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors; Phosphatidylinositol 3 kinase gamma modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Triple negative breast cancer
- Phase I/II Haematological malignancies; Hodgkin's disease; T-cell lymphoma
- No development reported Cutaneous T-cell lymphoma; Ovarian cancer; Peripheral T-cell lymphoma
Most Recent Events
- 03 Mar 2024 Phase-II clinical trials in Triple-negative-breast-cancer (Metastatic disease) in India (PO) (NCT06189209)
- 26 Dec 2023 Rhizen Pharmaceuticals in collaboration with Incozen Therapeutics plans a phase II trial for Triple negative breast cancer (Metastatic disease, Second-line therapy or greater) in India (PO) (NCT06189209)
- 02 Jun 2023 Efficacy and adverse events data from a phase II trial in Breast cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)